Treatment for Glioma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Indiana University School of Medicine, Indianapolis, IN
Glioma
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Through study completion, an average of 1 year.

Year 1
A list of which scans are necessary for statistically valid routine clinical classification of genomic abnormalities.
Accuracy of the mathematical algorithms to predict progression-free survival (PFS) and overall survival (OS).
Sensitivity of mathematical algorithms for identifying the presence of genomic mutations from the in vivo images alone.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase < 1

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year.

Trial Background

Jason Parker, PhD
Principal Investigator
Indiana University
Closest Location: Indiana University School of Medicine · Indianapolis, IN
Photo of indianapolis  1Photo of indianapolis  2Photo of indianapolis  3
2001First Recorded Clinical Trial
3 TrialsResearching Glioma
147 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to lay supine for up to 80 minutes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.